Australia · Research startup
Australia · GPN Vaccines
GPN Vaccines is a clinical-stage biotechnology company based in Adelaide and Canberra, Australia, founded in 2017.
Funding reportedLast round: Series B
Follow GPN Vaccines and see its new rounds in your feed.Start following
About GPN Vaccines
GPN Vaccines is a clinical-stage biotechnology company based in Adelaide and Canberra, Australia, founded in 2017.
The company is focused on developing a universal vaccine, Gamma-PN, against *Streptococcus pneumoniae*, which causes serious diseases like pneumonia and meningitis. GPN Vaccines aims to provide robust protection against all serotypes of this pathogen, addressing the limitations of existing vaccines that only cover a subset of strains. The company has successfully completed a Phase 1 study and is moving towards Phase 2 trials to further evaluate the safety and immunogenicity of Gamma-PN. GPN Vaccines has raised approximately $21.5 million in funding, including a significant Series B round in June 2024. Led by CEO Dr. Tim Hirst, the company is dedicated to advancing public health through innovative vaccine solutions, targeting both children and older adults, particularly those aged 70 and over, who are at higher risk for pneumococcal diseases.
What company datasets say GPN Vaccines raised
Funding, as reported
Founders and team
From GPN Vaccines's own website: 5 on the team.
- Antiksha JoshiDirector of Quality
- Malachi ObstResearch Officer
- Miriam DoddQuality Manager
- Peter MillsDirector of International
- Shawn LuoResearch Officer
AdvisersMPhil Student
On a portfolio page
Investors who name them
Each firm lists GPN Vaccines on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.
The company, in detail
What they build
Known for
health carevaccine efficacybiotechnology researchglobal health solutionsmanufacturingvaccine pipelinemedical researchimmunological assessmentmultiserotype protectionnonadjuvanted vaccinesstreptococcus pneumoniaeclinical researchhospital & health careimmune responsebroad-spectrum vaccinesmedical
Built with from their website
WistiaGoogle Tag ManagerWordPress.orgFont AwesomeCloudFlareViewport MetaBabelCloudFlare CDNPriority HintsCAPTCHA
+8 more
Microsoft ExchangeMySQLPrimeNGMicrosoft 365 Apps & ServicesMobile FriendlyOpen GraphjQueryRSS
- Sector
- Research
- Industry code
- NAICS 541714, 325414, SIC 2834
- Region
- Australian Capital Territory
- Full record
- Every detail in the company directory
Research in Australia
Startups like it
Is this your company?
Add your raise, your deck and your story, and put GPN Vaccines in front of investors. Or tell us what we have wrong.